XML 25 R6.htm IDEA: XBRL DOCUMENT v3.25.4
Condensed Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss $ (26,966,367) $ (16,290,695)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accretion of discount on marketable securities, net (854,077) (1,205,197)
Stock-based compensation expense 1,448,634 1,405,722
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 638,355 (641,089)
Deferred offering costs (310,581) 0
Accounts payable (67,322) 848,969
Accrued expenses and other liabilities 834,157 690,290
Grant receivable 1,827,238 (1,338,827)
Net cash used in operating activities (23,449,963) (16,530,827)
Cash flows from investing activities:    
Purchase of marketable securities (25,402,751) (48,101,129)
Maturities of marketable securities 43,500,000 19,440,000
Net cash provided by (used in) investing activities 18,097,249 (28,661,129)
Cash flows from financing activities:    
Proceeds from sale of common stock, prefunded warrants and common stock warrants 0 46,398,606
Net cash provided by financing activities 4,588,687 46,398,606
Net (decrease) increase in cash and cash equivalents (764,027) 1,206,650
Cash and cash equivalents at beginning of the year 8,999,496 7,792,846
Cash and cash equivalents at end of the year 8,235,469 8,999,496
Supplemental disclosure of non-cash investing and financing activities:    
Stock options granted in lieu of cash bonus 0 255,724
Cashless exercise of pre-funded warrants 0 945
Deferred offering costs in accounts payable 10,000 0
Open Market Sales Agreement [Member]    
Cash flows from financing activities:    
Sale of common stock under At-the-Market Sales Agreement, net of issuance costs $ 4,588,687 $ 0